Vascular calcification contributes to mortality and morbidity in atherosclerosis, chronic kidney disease, and diabetes. Vascular calcific lesions contain osteoblast-and chondroblast-like cells, suggesting a process of endochondral or membranous ossification thought to result from the phenotypic plasticity of vascular cells. Bone morphogenetic protein (BMP) signalling potentiates atherosclerotic calcification, whereas BMP inhibition attenuates vascular inflammation and calcification in atherogenic mice. We hypothesized endothelial cells (ECs) may undergo osteogenic differentiation in response to BMP signalling and pro-atherogenic stimuli.
Introduction
Vascular calcification is a highly prevalent condition associated with atherosclerosis, chronic kidney disease, diabetes, and hypertension, and is an independent predictor of morbidity and mortality in these conditions. 1 -3 Vascular calcification is a highly regulated process that requires coordinated function of molecular and cellular activators and inhibitors of bone formation, with evidence of simultaneous bone matrix formation, mineralization, and resorption during calcific remodelling of the vessel. 4, 5 Bone morphogenetic proteins (BMPs) are members of the transforming growth factor (TGF)-b pathway that play essential roles in early embryonic patterning and organogenesis. BMP signals specify the fate of vascular progenitors during vasculogenesis, and contribute to vascular remodelling in a variety of acquired and congenital disorders. 6 -9 The findings that BMPs are overexpressed in the lesions of calcific atherosclerosis 10 and that smooth muscle-targeted overexpression of BMP2 accelerates vascular calcification in atherogenic (apoE 2/2 ) mice 11 suggest that BMP signals regulate vascular calcification. In support of this concept, vascular calcification is attenuated in ApoE 2/2 mice that also overexpress matrix Gla protein (MGP), a vitamin K-dependent calcium-binding extracellular matrix protein which functions as an endogenous BMP inhibitor, whereas MGP-deficient mice develop spontaneous and severe vascular calcification. 12 -14 We recently found that pharmacological BMP inhibition reduces vascular inflammation and calcification in Low density lipoprotein receptor-deficient (LDLR 2/2 ) mice fed an atherogenic diet. 15 In this study, oxidized LDL (oxLDL) induced oxidative stress in endothelial cells (ECs) in a BMP-dependent manner, consistent with prior observations that BMP2 induces calcification of cultured EC in an oxidative stressdependent manner. 16 Recently, Yao et al. found that Tie2-marked endothelial-related lineages contribute osteoprogenitors to the calcific vascular lesions of MGP-deficient and Ins2Akita/+ diabetic mice. 17 Other reports have also suggested that ECs harbour osteogenic and chondrogenic potential, 18, 19 and may contribute to heterotopic ossification in other tissues due to aberrant BMP signalling. 20 Taken together, these data suggest that BMP signalling may exert some of its pro-osteogenic and inflammatory effects in the vasculature by acting on the endothelium, and may directly affect the plasticity of those lineages. Inflammation is understood to be a necessary precedent for physiologic and pathophysiologic ossification. Atherogenic stimuli such as oxLDL appear to exert their effects through a number of different cell types, which include tissue-associated macrophages and their inflammatory cytokines, 21, 22 as well as endothelium itself via engagement of LOX-1 receptors, with resulting activation of NAD(P)H oxidase and oxidative stress. Here we hypothesized that the inflammatory and pro-oxidant effects of oxLDL may contribute directly to osteogenic activity in EC, and in a manner that may be cooperative with or require BMP signalling. We examined the ability of oxLDL and BMP signals to elicit inflammation and oxidative stress, to alter gene expression and thereby induce osteogenic differentiation and calcification in cultured ECs. We demonstrate multiple levels of synergy between BMP signalling and atherogenic stimuli in regulating EC phenotypic plasticity, principally via oxidative stress. These findings provide potential mechanisms for the contribution of endothelial BMP signalling in the pathophysiology of atherosclerosis and vascular calcification.
Methods

Chemicals and reagents
Recombinant human BMP ligands were purchased from R&D Systems, Minneapolis, MN, USA. Purified oxLDL and native LDL from human plasma were obtained from Biomedical Technologies (Ward Hill, MA, USA). Primary antibody against phosphorylated-Smad 1/5/8 was purchased from Cell Signaling (Danvers, MA, USA).
Cell culture
Bovine aortic endothelial cells (BAEC) were purchased from Lonza (Walkersville, MD, USA) and maintained in high glucose DMEM supplemented with 10% fetal bovine serum (FBS). Human aortic endothelial cells (HAEC) were purchased from Lonza and maintained in EBM-2 with EGM-2 supplement. BAEC were incubated with 0.5% FBS, and HAEC were incubated with 1% FBS without growth supplements to achieve quiescence before experimental stimuli. Human dermal fibroblasts (Lonza) were cultured in DMEM/F12 supplemented with 10% FBS. MC3T3-E1 cells (ATCC, Manassas, VA, USA) and maintained in Alpha Minimum Essential Medium supplemented with 10% FBS. Where noted, quiescent cells were treated with inhibitors for 30 min before experimental stimuli.
Alkaline phosphatase activity assay
Alkaline phosphatase (ALP) activity was assayed in BAEC and MC3T3-E1. 
Osteogenic differentiation and mineralization in osteogenic medium
EC were seeded in gelatin-coated 96-well plates at a density of 4000 cells per well, and incubated in reduced serum media to achieve quiescence. Cells were treated with or without BMP6 (30 ng/mL) sequentially or simultaneously with oxLDL (100 mg/mL) for 3 days, and maintained in osteogenic medium for up to 3 weeks. Osteogenic medium consisted of ascorbic acid (0.2 mM), dexamethasone (0.1 mM), and b-glycerophosphate (10 mM). EC were fixed and stained with Alizarin red (AR) and analysed by microscopy (×20 magnification), or quantitated by eluting with 10% formic acid and measuring absorbance at 414 nm and expressed as optical density unit. Background AR staining by culturing BAEC in regular growth medium and its absorbance was subtracted from all the treatment groups.
Immunofluorescence
Cells were cultured as described in chamber slides, and then fixed in 1% PFA with 1% Triton X-100. Cells were blocked in 5% goat serum in phosphate buffered saline for 60 min at RT, and then incubated with either murine monoclonal anti-smooth muscle a-actin (Sigma-Aldrich 
Quantitative RT-PCR
EC were seeded in six-well plates, and treated with ligands. RNA was harvested using TRIZOL reagent as described previously. Reverse transcription was performed using Moloney murine leukaemia virus reverse transcriptase (Promega, Madison, WI, USA). Expression of osteogenic and chondrogenic transcription factors were quantified using real-time PCR (Eppendorf). Changes in expression of target transcript were normalized to GAP(D)H and determined using relative C T method. Primer sequences were summarized in Supplementary material online, Table S1 .
Measurement of reactive oxygen species production
Impact of reactive oxygen species (ROS) production was measured using CellROX Deep Red Reagent (Life Technologies). BAEC were seeded in 96-well plates and incubated in serum-free media overnight before exposure to either BMP6 or oxLDL for the time point indicated. Cells were then treated with 5 mM CellROX Deep Red Reagent for 30 min. Absorbance at 665 nm was measured using Varioskan Flash Multimode Reader (Thermo Fisher, Cambridge, MA, USA).
Statistical analysis
Data are presented as mean + SEM and compared between groups using the Student's t-test, or by one-way analysis of variance (ANOVA), using Tukeys' multiple comparison test for post hoc analysis, with P , 0.05 considered statistically significant.
Results
Canonical BMP signalling in bovine aortic endothelial cells (BAEC) was measured via the detection of phosphorylated-Smads 1, 5, and 8 by immunoblot ( Figure 1A) , and by the expression of early response gene Id1 mRNA ( Figure 1B) . Among several BMPs ligands tested, BAEC were most responsive to BMP6 and BMP9, with an approximate EC 50 of 10 ng/mL for BMP6-induced Id1 expression ( Figure 1C) . We next examined the potential osteogenic effects of these ligands in BAEC via cellular alkaline phosphatase activity measured 48 -72 h after stimulation. Of these ligands, BMP6 up-regulated alkaline phosphatase activity most potently ( Figure 1D ), and did so in a dose-dependent manner ( Figure 1E ), confirmed also by immunochemical staining (Supplementary material online, Figure S1 ). To examine the impact of BMPs and oxLDL upon osteogenic differentiation of ECs in vitro, BAEC were exposed to BMP6 (30 ng/mL) and/or oxLDL (100 mg/mL), and cultured in osteogenic medium for 3 weeks. AR staining was performed to assess the degree of mineralization. BMP6 or oxLDL were independently active, but highly synergistic in their capacity to enhance mineralization ( Figure 1F and G). In contrast, treatment with native LDL did not elicit mineralization in BAEC (Supplementary material online, Figure S2 ). To rule out the possibility that these osteogenic effects were due to contamination with fibroblast or smooth muscle cells in primary cultures, we tested the expression of endothelial vs. smooth muscle cell markers in cultured BAEC. Consistent with a high degree of purity of ECs, vWF was homogeneously expressed, and smooth muscle a-actin was homogeneously absent in BAEC primary cultures at low passages similar to those used for differentiation experiments (Supplementary material online, Figure S3 ).
To gain insight into how BMP6 and oxLDL might interact to elicit osteogenic differentiation, the expression of several osteogenic and chondrogenic transcription factors was measured in EC following treatment with BMP6 and/or oxLDL. Treatment of BAEC with Figure 1 BMP6 and oxLDL synergistically regulate osteogenic potential in BAEC. BAEC were deprived of serum overnight and exposed to BMPs 2, 4, 6, or 9 at 10, 30 or 50 ng/mL. Among the BMPs examined, BMP6 and 9 elicited Smad 1/5/8 phosphorylation at 30 min (A) and Id1 mRNA expression at 1 h (B) most potently. BAEC were exposed to BMPs (50 ng/mL) for 72 h and alkaline phosphatase activity was measured. Only BMP6 enhanced alkaline phosphatase activity, doing so in a dose-dependent manner (D and E). Data are represented as mean + SEM, n ¼ 4. *P , 0.05, **P , 0.01, ***P , 0.001 when compared with control. Combined treatment of BMP6 and oxLDL synergistically enhanced calcification under osteogenic conditions (F and G). BAEC were treated with BMP6 (30 ng/mL) and/or oxLDL (100 mg/mL) and maintained in osteogenic medium for 3 weeks, with mineralization assayed by AR staining. Scale bars ¼ 100 mm (F ). Mineralization was quantitated by eluting AR with 10% formic acid and measuring absorbance at 414 nm. Background (control condition in which BAEC were maintained in regular growth medium for 3 weeks) was subtracted from all the treatment groups. Data are represented as mean + SEM from four independent experiments. *P , 0.05, ***P , 0.001 as indicated (G).
BMP6 (30 ng/mL) up-regulated osteogenic (Runx2 and Opn) and chondrogenic (Msx2) transcription factors within 36 h of treatment ( Figure 2A) , following early and sustained expression of Id1. Exposure of BAEC to oxLDL (100 mg/mL) up-regulated Runx2, Msx2, Osterix, and Opn mRNA within 36 h of treatment, and was itself associated with a modest but significant increase in Id1 ( Figure 2B ). Murine MC3T3-E1 pre-osteoblast cells were used as a control cell line to provide a benchmark for BMP-induced osteogenic differentiation and the expression of osteogenic transcription factors. We found that BMP2, and to a greater degree BMP6 enhanced alkaline phosphatase activity and up-regulated the expression of Runx2 mRNA in MC3T3-E1 (Supplementary material online, Figure S4 ), both to a degree similar to that observed in BAEC. These results suggest BMP signalling induces osteogenic activity and gene expression comparably in BAEC and a pre-osteoblastic cell line, and that BMP6 is a potent regulator of such activity in both cell types.
In BAEC, treatment with oxLDL induced Col1a1 and Col2a1 (Supplementary material online, Figure S5 ), consistent with chondrogenic and endochondral differentiation. It has been previously observed that ECs can be induced to express smooth muscle a-actin following stimulation with TGF-b ligands, 23 suggesting differentiation to a smooth muscle fate. Importantly, treatment with BMP6 or oxLDL did not induce the expression of smooth muscle a-actin or smooth muscle myosin heavy chain (Figure 3) , demonstrating that the osteogenic effects of these stimuli did not require intermediate differentiation to smooth muscle. Rather, treatment with BMP6 or oxLDL transiently suppressed the expression of all endothelial, mesenchymal, and smooth muscle markers tested for the first 24 h following stimulation. At 36 and 48 h, however, oxLDL significantly up-regulated CD31, CD44, and CD71, demonstrating that this treatment first induced de-differentiation, followed by the co-expression of mesenchymal and endothelial markers in addition to osteogenic genes (Figures 2 and 3) . As suggested by the lack of osteogenic activity in the alkaline phosphatase assay, BMP9 exposure did not alter the expression of osteogenic and chondrogenic transcription factors in BAEC (Supplementary material online, Figure S6 ).
To explore the basis of the synergy between BMP6 and oxLDL in mediating osteogenic differentiation and mineralization, the expression of endochondral transcription factors was examined in BAEC cotreated with BMP6 and oxLDL Figure 4A-D) .
The up-regulation of Id1 following treatment with oxLDL alone suggested that oxLDL might enhance BMP signalling activity, a possibility we examined further by measuring the expression of various BMP ligands following stimulation with oxLDL. Treatment of BAEC with oxLDL significantly increased Bmp2 and Bmp9 mRNA expression, without affecting Bmp4 or Bmp6 at 36 h ( Figure 4E -H ) . The induction of Bmp2 and Bmp9 expression suggested possible mechanisms for the modest increase in Id1 expression due to treatment with oxLDL, given that both of these ligands were active signalling molecules in these cells ( Figure 1B) . Since neither of these ligands were highly osteogenic in BAEC ( Figure 1D) , it was reasoned that oxLDL might engage other mechanisms to induce osteogenic differentiation. Of note, treatment with Figure 2 Treatment with BMP6 and oxLDL induced the expression of distinct and overlapping osteogenic transcription factors in ECs (A and B). BAEC were deprived of serum overnight and exposed to BMP6 (30 ng/mL) or oxLDL (100 mg/mL) for varying intervals up to 72 h. Levels of mRNA expression were normalized to Gapdh and compared with controls. Data are represented as mean + SEM, n ¼ 4. ***P , 0.001 by one-way ANOVA, and compared with controls using Tukeys' multiple comparison test.
BMP6 itself up-regulated Bmp6 mRNA expression ( Figure 4G ), suggesting the possibility of positive feedback via this ligand in regulating osteogenic activity.
To ascertain the involvement of oxidative stress in mediating EC mineralization, ROS production was measured via the oxidationinduced fluorescence of free-radical sensing probe CellROX Deep Red. Over the course of 48 h, treatment with oxLDL, BMP6, or both elicited ROS over-production individually and synergistically ( Figure 5A and B) . To test the possibilities that canonical BMP receptor signalling and oxidative stress contribute mutually to EC mineralization in response to these stimuli, we employed the selective BMP type I receptor inhibitor, LDN-193189, 24, 25 and the ROS scavenger, Tempol.
As might be expected, LDN-193189 abrogated the up-regulation of Runx2, Msx2, Osterix, and Opn in response to BMP6 at 36 h ( Figure 5C ). Interestingly, treatment with Tempol also prevented the induction of Msx2, Osterix, and Opn in response to BMP6. Treatment with Tempol, but not LDN-193189, prevented oxLDL-induced upregulation of Runx2, Msx2, Osterix, and Opn ( Figure 5D ). These results suggested that the osteogenic activity of BMP6 is partly dependent on ROS activation, whereas the osteogenic activity of oxLDL does not require BMP signalling activity. However, when we examined the effects of BMP receptor inhibition and ROS scavenging on mineralization, either LDN-193189 or Tempol effectively prevented mineralization induced by BMP6, oxLDL, or the combination of BMP6 and oxLDL at 3 weeks ( Figure 6A and B) , suggesting essential roles of BMP signalling and ROS activation for mineralization in response to BMP6 or oxLDL. To investigate whether or not oxidative stress itself regulates the expression of osteogenic and chondrogenic transcription factors in EC, the impact of treating BAEC with H 2 O 2 was assessed. Exposure to H 2 O 2 dose-dependently up-regulated Runx2, Msx2, and Osterix mRNA in BAEC ( Figure 7A ). Similar to our finding that treatment with oxLDL enhanced the expression of Bmp2 and Bmp9 ( Figure 4E-H ), exposure of BAEC to H 2 O 2 potently up-regulated Bmp2 and Bmp9 mRNA, and modestly increased Bmp4, but not Bmp6 (Figure 7B -E) . There was no significant interaction between the activity of BMP6 and H 2 O 2 in mediating these effects on ligand expression.
Finally, we examined whether or not these synergistic effects of BMP and atherogenic stimuli were recapitulated in HAEC. Similar to our findings in BAEC, treatment of HAEC with BMP6 or oxLDL up-regulated Figure S7A and B). As was the case for BAEC, HAEC exhibited a high degree of homogeneity in the expression of endothelial lineage markers, and the absence of smooth muscle markers (Supplementary material online, Figure S3 ). In further support of an osteogenic and chondrogenic effect, treatment of HAEC with BMP6 or oxLDL also greatly enhanced the expression of Col1Aa1, Col2a1, and Sox9. Finally, combined treatment with BMP6 and oxLDL in the presence of osteogenic medium induced mineralization in HAEC to a greater extent than treatment with either stimuli alone (Supplementary material online, Figure S7C and D).
Discussion
In this study, we sought mechanistic insights to explain previous observations that BMP signalling contributes to vascular inflammation and calcification associated with atherosclerosis. 10, 14, 15, 26 We began with the novel observation that BMP-mediated signalling and proatherogenic stimuli interact synergistically to regulate osteogenic differentiation and mineralization in EC. As a potential mechanism for their interaction, we found that BMP6 and oxLDL individually and synergistically regulate the expression of Osterix, a critical transcriptional regulator of osteoblast differentiation, and Osteopontin (Opn), an extracellular matrix protein elaborated by osteoblasts and osteoclasts critical for bone development and remodelling. Importantly, we show that BMP6 and oxLDL both require ROS activation to mediate the expression of osteogenic genes, osteogenic differentiation, and calcification. We found that ROS itself directly induces osteogenic and chondrogenic transcription factors in EC. Thus, BMP signals and atherogenic stimuli may interact by exerting overlapping effects on oxidative stress and endochondral transcriptional programs in the vascular endothelium. Our finding that osteogenic differentiation of EC is promoted by a combination of BMP signalling and atherogenic stimuli support the growing concept that endothelial plasticity may contribute to a variety of disease phenotypes including atherosclerosis. 17 The transcriptional and histological features of vascular calcification recapitulate embryonic endochondral and membranous ossification, and have been interpreted to reflect phenotypic and lineage plasticity of vascular cells in response to inflammatory and metabolic insults. 10, 27, 28 While vascular smooth muscle cell (VSMC)-related lineages have also been implicated in MGP-deficient and atherosclerotic models of vascular calcification, 29 the potential contribution of endothelium has been highlighted in atherosclerotic and diabetic models of vascular calcification. 17 The ability of endothelial lineages to develop characteristics of mesenchyme was first discovered in developing heart, where endocardium transdifferentiates to form the atrioventricular cushion via a process also known as endothelial mesenchymal transition or EndMT. 30 -32 This process occurs in the outflow tract and the atrioventricular canal, and is thought to be mediated by inductive signals from TGF-b and BMP ligands. Zeisberg et al. showed that cardiac EC may undergo EndMT to contribute to cardiac fibrosis in adult murine heart. 33 Other lines of evidence have suggested that a postnatal process resembling developmental EndMT contributes to heterotopic ossification, 20 the general phenomenon of ectopic bone formation within soft tissues, as well as a variety of pathophysiologic processes involving fibrotic remodeling. 34 -38 While lineage-marking experiments using the activity of broadly expressed promoters such as Tie2 have suggested a potential contribution of endothelial-related lineages to disease lesions, 17, 20, 39 recent studies have suggested that Tie2-mediated lineage marking includes a substantial number of non-endothelial and non-vascular cells. 40 Thus, further studies which directly examine the osteogenic potential cells identified by specific phenotypic markers of terminally differentiated endothelial lineage in vivo following postnatal development are needed to evaluate this concept rigorously. Our current study examined the ability of cultured EC to undergo osteogenic transcription and in vitro calcification as potential surrogates of this biological process, specifically to understand the interaction of two of the most important contributors to vascular calcification in vivo, atherogenesis, and BMP signalling.
As an atherogenic stimulus, oxLDL has been previously observed to induce ROS production and reduce NO bioavailability in ECs, with consequences which include uncoupling of eNOS activity, endothelial dysfunction, and apoptosis. 41 -43 The present work examined potential cross-talk between oxLDL and BMP pathways, demonstrating an essential role of oxidative stress mediating EC mineralization in response to either stimulus, as well as the combination. Synergy between BMPs and atherogenic lipids mediated by oxidative stress could contribute to vascular inflammation during the early phases of atherosclerosis. Towards identifying the cellular source of ROS, we found that specific inhibition of NAD(P)H oxidase abolished the up-regulation of osteogenic and chondrogenic transcription factors in cells exposed to oxLDL, suggesting that NAD(P)H oxidase is the primary enzymatic source of ROS in this process (Supplementary material online, Figure S8 ). Follow-up studies on the spatiotemporal regulation of NAD(P)H oxidase, its inhibitors, and other antioxidant enzymes in ECs would be warranted to characterize this mechanism in more detail. In addition to direct effects on EC via LOX1 receptors, oxLDL may be absorbed by infiltrating inflammatory cells to give rise to foam cells at sites of endothelial injury. Macrophage-mediated inflammation has been shown to regulate the osteogenic differentiation and mineralization of cultured VSMC, 21 and could contribute via the elaboration of ROS or other mediators. VSMC undergo osteogenic differentiation in response to macrophagederived cytokines including interleukin-1b, interleukin-6, interleukin-8, and tumour necrosis factor-a. 22 Thus, beyond the cell-autonomous effects of oxLDL upon EC investigated in this work, the paracrine effects of oxLDL-mediated activation of macrophages upon EC plasticity and their possible interactions with BMP signalling in either lineage would be an important subject of further investigation. Exposure to oxLDL slightly increased the expression of the BMP transcriptional target Id1 in cultured EC, providing another avenue ECs. Level of ROS production was measured using CellROX Deep Red Reagent. BAEC were treated with BMP6 and/or oxLDL for 18 h (A) or 48 h (B). Data are shown as mean + SEM, n ¼ 4. *P , 0.05, **P , 0.01, and ***P , 0.001 as shown. BAEC were treated with a BMP inhibitor (LDN-193189, 100 nM) or a ROS scavenger (Tempol, 100 mM) prior to BMP6 (30 ng/mL, C) or oxLDL (100 mg/mL, D) treatment for 36 h. Data are shown as mean + SEM, n ¼ 4. *P , 0.05, **P , 0.01, and ***P , 0.001 compared to BMP6-or oxLDL-treated cells.
for synergistic interactions between BMP and atherogenic stimuli. As we observed previously, exposure to oxLDL was responsible for the upregulation of selected BMP ligands, 15 providing a potential explanation. However, oxLDL did not induce the expression of the highly osteogenic ligand Bmp6, but instead induced the expression of Bmp2 and Bmp9, both weakly osteogenic in our experimental system. BMP9 is a critical vascular homeostatic factor found to circulate at biologically active concentrations and that is known to negatively regulate endothelial apoptosis, migration, and angiogenic remodeling. 44, 45 Consistent with these homeostatic functions, BMP9 was not found to be osteogenic in BAEC, and in fact, BMP9 effectively prevented cell death in BAEC exposed to oxLDL (Supplementary material online, Figure S9 ). While BMP2 or BMP9 are not potently osteogenic by themselves, oxLDL-induced or H 2 O 2 -mediated BMP2 and/or BMP9 signalling might potentiate canonical BMP signalling provided by osteogenic ligands when combined with oxLDL or ROS activation. Considering the homeostatic functions of BMP9, and the potent up-regulation of Bmp9 mRNA in EC following treatment with oxLDL or H 2 O 2 , the expression of BMP9 in EC might represent a negative feedback mechanism to counteract injury in response to oxidative stress. Figure 6 BMP receptor-mediated signalling and oxidative stress contributed to mineralization in ECs. BAEC were treated with a BMP inhibitor (LDN-193189, 100 nM) or ROS scavenger (Tempol, 100 mM) prior to BMP6 (30 ng/mL, A) and/or oxLDL (100 mg/mL, B) treatment. BAEC were maintained in osteogenic medium for 3 weeks. The degree of mineralization was determined by AR staining. Scale bars ¼ 100 mm (A). AR staining was quantitated by elution with 10% formic acid and measuring absorbance at 414 nm (B). Data are mean + SEM, n ¼ 4. *P , 0.05, **P , 0.01, and ***P , 0.001 as indicated.
The present data provide several novel mechanisms to explain the synergy between atherogenic stimuli and the long-observed phenomenon of enhanced BMP signalling in the vasculature associated with atherosclerosis and vascular calcification. 10, 26 Gain-of-function or aberrant activity of the BMP signalling pathway has been subsequently observed in models of vascular dysfunction and inflammation associated with chronic kidney disease, 46 diabetes, 47 as well as atherosclerosis. 10 Consistent with the functional relevance of these BMP signals, work from our group and others suggests that inhibiting vascular BMP signalling via ligand traps or small molecule inhibitors of BMP type I receptor kinases may be useful in attenuating vascular inflammation and calcification. 15, 48 Our current finding that atherogenic stimuli and BMP signals must exert their effects via oxidative stress would provide additional rationale for the use of agents known to exert both anti-oxidant and lipid-lowering effects, such as statins, or suggest the deployment of novel anti-oxidant strategies, including BMP inhibition, as a means for attenuating this important interaction.
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Figure 7
Oxidative stress directly regulated the expression of chondrogenic and osteogenic transcription factors and BMP ligands in ECs. BAEC were exposed to H 2 O 2 (100 nM, 1 mM or 10 mM) for 36 h. Expression levels of Runx2, Msx2, Osterix, and Opn mRNA were normalized to Gapdh and compared to control (A). In a separate experiment, BAEC were treated with H 2 O 2 (1 mM) with or without BMP6 (30 ng/mL) for 36 h, and changes in the mRNA expression of BMP ligands were examined (B -E). Data are shown as mean + SEM, n ¼ 4. *P , 0.05, **P , 0.01, and ***P , 0.001 as indicated.
